Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Part of paid clinical trials in Providence, Rhode Island.

Sponsor
Brown University
Study ID
NCT04135846
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Alcohol Use Disorder (AUD)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Doxazosin — DRUG
    16 mg or maximum tolerated dose (MTD)
  • Placebo — DRUG
    Matching placebo

Study Details

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

Key Dates

Start date
Dec 19, 2019
Status verified
Sep 2025
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
184 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: doxazosin
    16 mg, or maximum tolerated dose (MTD)
  • Placebo Comparator: placebo
    matching placebo

Primary Outcome Measure

Alcohol consumption [ Time Frame: 6 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Brown UniversityProvidenceRhode Island20923
Zoe Brown
401-863-6646

Find similar trials in Providence, RI

By research site
Brown University· Providence, RI

Related Studies